CKMH Nephrology
There is no content available at this time. Please check again later.
Relevant Content
Women's Kidney Health in Focus
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy
uPAR/suPAR Signaling and Organ Crosstalk in Cardiovascular-Kidney-Metabolic Syndrome
Globally, one in 10 women lives with chronic kidney disease (CKD), which i...
Time of Day as a Biological Variable in Cardiovascular and Kidney Disease Research
Time-of-day is a fundamental biological variable that needs to be consider...
Finerenone Plus Empagliflozin: How Low Can We Go, and How Much Does Blood Pressure Matter?
Hypertension, Volume 83, Issue 9, Page e27364, September 1, 2026.
Letter by Hu et al Regarding Article, “Cell-Specific Inducible Human APOL1 Risk Variant Expression in Mice Causes Hypertension and Renal Damage”
Circulation, Volume 154, Issue 6, Page e235-e236, August 11, 2026.
Response by Poudel and Susztak to Letter Regarding Article, “Cell-Specific Inducible Human APOL1 Risk Variant Expression in Mice Causes Hypertension and Renal Damage”
Circulation, Volume 154, Issue 6, Page e237-e238, August 11, 2026.
Methodologic Standards for Follow-Up Extension in Cardiovascular Trials
Extension follow-up studies address long-term questions beyond the parent...
Comprehensive Clinical Approach to Cardiovascular Kidney Metabolic Syndrome
Polypharmacy is common in cardiovascular (CV) care because guideline-direc...
Researchers at Heart
Circulation Research, Volume 139, Issue 1, Page e328563, June 19, 2026.
Loading...
Save Video
Please note: American Heart Association does not associate with, nor endorse YouTube recommendations.
Video is not available. Please check the URL.